Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal-Reference-Cited by-同舟云学术

Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Published:2023-05-02 Issue:8 Volume:41 Page:857-867
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Witlox Willem^ORCID,Grimm Sabine,Howick Jeremy,Armstrong Nigel,Ahmadu Charlotte,McDermott Kevin,Otten Thomas,Noake Caro,Wolff Robert,Joore Manuela

Funder

Health Technology Assessment Programme

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-023-01272-9.pdf

Reference27 articles.

1. Celgene Ltd. Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]: Document B (v2.0). Submission to National Institute of Health and Care Excellence. Single technology appraisal (STA); 2022. Accessed 11 Jan 2022.

2. Howick J, Witlox W, Ahmadu C, Grimm S, Armstrong N, McDermott K, et al. Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]: a Single Technology Assessment. York: Kleijnen Systematic Reviews Ltd; 2022.

3. National Institute for Health and Care Excellence. Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy: NICE technology appraisal guidance 827 [Internet]. London: NICE; 2022. https://www.nice.org.uk/guidance/ta827. Accessed 13 Jan 2023.

4. National Institute for Health and Care Excellence. Single Technology Appraisal: Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]: Committee Papers [Internet]. London: NICE; 2022. https://www.nice.org.uk/guidance/ta827/evidence/appraisal-consultation-committee-papers-pdf-11246852557. Accessed 13 Jan 2023.

5. National Institute for Health and Care Excellence. Health Technology Appraisal: Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy: final scope [Internet]. London: NICE; 2021. https://www.nice.org.uk/guidance/gid-ta10775/documents/final-scope. Accessed 7 Dec 2021.